Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the North American Cystic Fibrosis Conference (NACFC) | ||
By: Nasdaq / GlobeNewswire - 18 Oct 2018 | Back to overview list |
|
ELX-02 shows significant increases in CFTR function in Cystic Fibrosis patient-derived ELX-02 demonstrated significant increases in CFTR mRNA, with elevations above wild- WALTHAM, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”), (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced positive data demonstrating that ELX-02 showed significant increases in CFTR functional assay (P<0.0001) and mRNA levels (P<0.05) across multiple CFTR nonsense mutations in cystic fibrosis patient-derived organoids. ELX-02 demonstrated significant forskolin-induced swelling (FIS) in cystic fibrosis patient-derived organoids carrying homozygous and compound heterozygous CFTR nonsense mutations. These findings were presented today at the North American Cystic Fibrosis Conference in Denver, Colorado. “We are extremely pleased with the emerging profile of ELX-02, as the first read-through agent to demonstrate increases in CFTR function and mRNA in organoids derived from cystic fibrosis patients with nonsense mutations,” said Neal Sharpe, Ph.D., Vice President of Translational Sciences at Eloxx. “There is a high unmet medical need among the estimated 13% of cystic fibrosis patients with a nonsense mutation, as they have a high burden of disease and few, if any, treatment options.” Recent work with cystic fibrosis patient-derived organoids have extended the potential applications of the FIS assay to include use in stratifying patient disease severity (1) and as a potential predictor of CF patient response to drug therapy (2). Eloxx plans to initiate a Phase 2 study in cystic fibrosis patients carrying at least one G542X mutation. The European Cystic Fibrosis Society-Clinical Trial Network has reviewed the program and assigned a “high priority” rating. Eloxx expects to report top-line data from the Phase 2 study in 2019. In a Poster presentation titled “Measuring mRNA levels in cystic fibrosis organoids with nonsense mutations following treatment with ELX-02,” presented by Neal Sharpe, Ph.D., V. P. Translational Science, Eloxx reported that:
ELX-02 is an investigational agent not approved by any regulatory agency for therapeutic use. About Organoids Organoids are derived from stem cells isolated from cystic fibrosis patients and are differentiated into cell types found in organs of interest. Because organoids are made from stem cells, they contain the same mutations as the person from whom the biopsies originated. As CFTR functional activity is measurable in organoids, this model system is used to evaluate drug candidates across a range of mutations found in the cystic fibrosis patient population. Since some therapeutic candidates target the basic defect of cystic fibrosis, organoids are being evaluated as a potential biomarker to help identify which treatments can affect specific mutations.
About Eloxx Pharmaceuticals Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx’s preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides identified based on read-through potential. Eloxx recently announced a new program focused on rare ocular genetic disorders. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel. For more information, please visit www.eloxxpharma.com. Forward-Looking Statements Contact: |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |